Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The long-term chronic inflammation of cervical intraepithelial neoplasia (CIN) induces the initiation and progression of cervical cancer. Long non-coding RNAs (LncRNAs) are being identified to be involved into inflammation and carcinogenesis and could function as cancer biomarkers in clinical. However, the significance of inflammation-related LncRNA (e.g.
LncRNA-IL7R
) in cervical cancer is limited. We, here, investigated the clinical role of inflammation-related
LncRNA-IL7R
(
Lnc-IL7R
) in healthy cervical tissue (
n
=15),
CIN 1
/2/3 (
n
=35), cervical cancer (
n
=70), and clarified its function via knockdown
in vitro
and
in vivo
The results showed that the expression of
Lnc-IL7R
was increased from normal tissues to neoplastic lesions and cervical cancer. Up-regulated
Lnc-IL7R
positively correlated to tumor size, International Federation of Gynaecology and Obstetrics (FIGO) stage, and lymph node metastasis (LNM). Patients with high expression of
Lnc-IL7R
had poor prognosis with short overall survival (OS) time, and Cox regression analysis revealed that
Lnc-IL7R
could be independent prognostic factor for cervical cancer. Moreover, knockdown of
Lnc-IL7R
by two different siRNAs in cervical cancer cell lines Hela and SiHa induced impaired cell vitality and
caspase-3
-dependent apoptosis
in vitro
Furthermore, inhibition of
Lnc-IL7R in vivo
significantly restricted the tumor growth with decreased expressions of proliferation index Ki-67 and
Lnc-IL7R
These data indicated that
Lnc-IL7R
predicts a poor clinical outcome of cervical cancer patients, and knockdown of
Lnc-IL7R
is amenable to the treatment of cervical cancer.
...
PMID:Up-regulation of inflammation-related LncRNA-IL7R predicts poor clinical outcome in patients with cervical cancer. 2972 Apr 27